the plans set out by the
government.
Novartis is part of a
World Economic Forum
initiative on leapfrogging
in health. I really do
believe that emerging
economies can leapfrog
over countries in Europe
and North America to
find new ways to deliver
quality healthcare. And I
am convinced that India
has the ambition to do
exactly that.
Which are the areas
of healthcare in India
that Novartis Access
will be focusing upon
with immediate
priority?
The focus of Novartis
Access on NCDs does not
mean that we will neglect
infectious diseases. Our
Malaria Initiative, for
example, is still going
strong. We are very
proud of the work we
have done with malaria,
delivering more than
800 million treatments
since 2001, and currently
leading two of the world’s
most advanced malarial
medicine development
program. In India, where
one in seven people are
at risk of contracting
malaria, this is of
paramount importance,
as many of those afflicted
will be from rural areas –
the exact areas Novartis
is trying to target through
our Social Business
programs.
UHC is not a
“one-size-fits-
all” approach and
models that work
in Europe or the
US